The 9158.T stock jumped 11.34% at the JPX close on 04 Feb 2026, driven by a volume surge of 695,800.00 shares versus an average of 157,803.00. Traders pushed the price from the open ¥867.00 to close at ¥903.00, hitting a day high of ¥911.00 and a day low of ¥851.00. This high-volume move put CUC Inc. (9158.T) back on traders’ radars, highlighting valuation gaps and near-term technical support levels.
9158.T stock: high-volume move and intraday action
Volume was the headline. 695,800.00 shares traded, a relative volume of 4.41, signaling institutional or concentrated retail activity. The stock closed at ¥903.00, a gain of ¥92.00 from the prior close of ¥811.00, and the surge broke a short consolidation around ¥866.50 (50-day middle Bollinger band).
9158.T stock fundamentals and valuation
CUC Inc. reports EPS ¥59.20 and a P/E of 15.25, below the healthcare sector average P/E. Price-to-book sits near 0.88, and price-to-sales is 0.51, implying the market values the company at a discount to peers. Market cap stands at ¥26,471,724,027.00 with 29,315,309 shares outstanding.
9158.T stock technicals and trend signals
Technicals show short-term weakness but a possible base. RSI reads 31.40, near oversold. ADX at 51.15 indicates a strong trend in place. Bollinger bands are ¥810.81 (lower) to ¥922.19 (upper), so the current close of ¥903.00 sits near the upper band today.
Meyka AI grade, forecast and price context for 9158.T stock
Meyka AI rates 9158.T with a score of 62.01 out of 100 (Grade B, HOLD). This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects ¥838.59 (monthly). Versus the current ¥903.00, that implies an implied downside of -7.14%. Forecasts are model-based projections and not guarantees.
9158.T stock catalysts and near-term drivers
Key near-term catalyst is the next earnings announcement on 2026-04-29. Company-level updates, dialysis capacity expansion, and management contracts could move sentiment. CUC is a subsidiary of M3 Inc., which may influence institutional flows and strategic partnerships.
9158.T stock risks, liquidity and sector comparison
Debt metrics show leverage pressure. Debt-to-equity is 1.74, and net-debt-to-EBITDA sits near 4.90, raising refinancing risk. Sector peers trade at higher P/E, so valuation upside needs earnings re-rating. Liquidity improved today with 695,800.00 volume but average liquidity remains moderate at 157,803.00.
Final Thoughts
CUC Inc. (9158.T) posted a clear high-volume breakout at the JPX close on 04 Feb 2026, with ¥903.00 intraday and 695,800.00 shares traded. Fundamentals give mixed signals: a reasonable P/E of 15.25 and low price-to-book at 0.88, but leverage metrics suggest caution. Meyka AI’s model projects ¥838.59 monthly, implying -7.14% versus the current price. For active traders, a near-term price target of ¥1,050.00 (implied upside +16.28%) and a 12-month target of ¥1,300.00 (+43.95%) frame scenarios if earnings and cash flow improve. These targets reflect a scenario where operational improvements and contract wins re-rate the stock. Remember, forecasts are model-based projections and not guarantees. See company filings at CUC corporate site and trading details on JPX for primary sources. For our live metrics and tools visit the Meyka stock page. Meyka AI provides this analysis as an AI-powered market analysis platform.
FAQs
What drove the 9158.T stock jump on 04 Feb 2026?
A large volume spike of 695,800.00 shares and intraday buying lifted the price to ¥903.00. The move followed renewed interest in healthcare services and short-term technical buying near ¥851.00 support.
How does 9158.T stock look on valuation metrics?
CUC shows P/E 15.25, EPS ¥59.20, price-to-book 0.88, and price-to-sales 0.51, indicating a relative discount to sector averages but higher leverage risk.
What is Meyka AI’s forecast for 9158.T stock?
Meyka AI’s forecast model projects ¥838.59 monthly for 9158.T stock, implying -7.14% versus the current ¥903.00. Forecasts are model-based and not guarantees.
What are main risks for 9158.T stock investors?
Primary risks include high net-debt-to-EBITDA (~4.90), debt-to-equity 1.74, and sensitivity to reimbursement and staffing trends in healthcare operations.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask our AI about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)